Back to Journals » Degenerative Neurological and Neuromuscular Disease » Volume 7 » default
Degenerative Neurological and Neuromuscular Disease
ISSN: 1179-9900
- View all (117)
- Volume 13, 2023 (3)
- Volume 12, 2022 (11)
- Volume 11, 2021 (6)
- Volume 10, 2020 (4)
- Volume 9, 2019 (11)
- Volume 8, 2018 (8)
- Volume 7, 2017 (10)
- Volume 6, 2016 (11)
- Volume 5, 2015 (12)
- Volume 4, 2014 (13)
- Volume 3, 2013 (8)
- Volume 2, 2012 (14)
- Volume 1, 2011 (6)
Archive: Volume 7, 2017

Erythrocyte membrane in the evaluation of neurodegenerative disorders
Sadanand A, Janardhanan A, Sankaradoss A, Vanisree AJ, Arulnambi T, Bhanu K
Degenerative Neurological and Neuromuscular Disease 2017, 7:127-134
Published Date: 17 October 2017

Current concepts in multiple sclerosis therapy
Sedal L, Winkel A, Laing J, Law LY, McDonald E
Degenerative Neurological and Neuromuscular Disease 2017, 7:109-125
Published Date: 28 September 2017

Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions

Ngo ST, Mi JD, Henderson RD, McCombe PA, Steyn FJ
Degenerative Neurological and Neuromuscular Disease 2017, 7:95-108
Published Date: 25 July 2017


Effects of a multimodal intervention on gait and balance of subjects with progressive multiple sclerosis: a prospective longitudinal pilot study


Bisht B, Darling WG, White EC, White KA, Shivapour ET, Zimmerman MB, Wahls TL
Degenerative Neurological and Neuromuscular Disease 2017, 7:79-93
Published Date: 26 June 2017

Characteristics of tongue and pharyngeal pressure in patients with neuromuscular diseases

Umemoto G, Furuya H, Tsuboi Y, Fujioka S, Arahata H, Sugahara M, Sakai M
Degenerative Neurological and Neuromuscular Disease 2017, 7:71-78
Published Date: 30 May 2017

Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis
Hinchcliffe M, Smith A
Degenerative Neurological and Neuromuscular Disease 2017, 7:61-70
Published Date: 29 May 2017

Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
Furber KL, Van Agten M, Evans C, Haddadi A, Doucette JR, Nazarali AJ
Degenerative Neurological and Neuromuscular Disease 2017, 7:47-60
Published Date: 24 March 2017

Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies
Feng JJ, Ontaneda D
Degenerative Neurological and Neuromuscular Disease 2017, 7:31-45
Published Date: 1 February 2017

Biomarkers of multiple sclerosis: current findings
Harris VK, Tuddenham JF, Sadiq SA
Degenerative Neurological and Neuromuscular Disease 2017, 7:19-29
Published Date: 12 January 2017

Randomized control trial evaluation of a modified Paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis: a pilot study
Irish AK, Erickson CM, Wahls TL, Snetselaar LG, Darling WG
Degenerative Neurological and Neuromuscular Disease 2017, 7:1-18
Published Date: 4 January 2017